Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:80909
Name castration-resistant prostate carcinoma
Definition A prostate carcinoma that is characterized by continued growth and spread despite the surgical removal of the testes or medical intervention to block androgen production.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer reproductive organ cancer male reproductive organ cancer prostate cancer prostate carcinoma castration-resistant prostate carcinoma

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
PTEN loss Abiraterone + Ipatasertib castration-resistant prostate carcinoma sensitive detail...
PTEN loss Enzalutamide + GSK2636771 castration-resistant prostate carcinoma no benefit detail...
PTEN inact mut CC-115 + Enzalutamide castration-resistant prostate carcinoma predicted - sensitive detail...
PIK3CA act mut CC-115 + Enzalutamide castration-resistant prostate carcinoma predicted - sensitive detail...
PTEN N323fs Everolimus castration-resistant prostate carcinoma predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT03436485 Phase Ib/II ODM-208 Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer (CYPIDES) Active, not recruiting USA | GBR | FRA 1
NCT03903835 Phase III Docetaxel Cabazitaxel Carboplatin Abiraterone Enzalutamide ProBio: A Biomarker Driven Study in Patients With Metastatic Castrate Resistant Prostate Cancer (ProBio) Recruiting BEL 3
NCT04434482 Phase I Senaparib + Temozolomide IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung Cancer Recruiting USA | AUS 3
NCT04717154 Phase II Ipilimumab + Nivolumab Ipilimumab With Nivolumab for Molecular-selected Patients With Castration-resistant Prostate Cancer (INSPIRE) Active, not recruiting NLD 0
NCT04839991 Phase I CB307 Study of CB307 in Patients With Advanced and/or Metastatic PSMA-positive Tumours. (POTENTIA) Recruiting USA | NLD | GBR | ESP 0
NCT04926181 Phase II Apalutamide + Cetrelimab Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer Active, not recruiting USA 0
NCT04946370 Phase Ib/II Pembrolizumab 225Ac-J591 + Pembrolizumab Maximizing Responses to Anti-PD1 Immunotherapy With PSMA-targeted Alpha Therapy in mCRPC Recruiting USA 0
NCT05005728 Phase II XmAb20717 Olaparib + XmAb20717 Cabazitaxel + Carboplatin + XmAb20717 XmAb20717 Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer Recruiting USA 0
NCT05057013 Phase Ib/II HMBD-001 HMBD-001 in Advanced HER3 Positive Solid Tumours Recruiting GBR 0
NCT05107674 Phase I NX-1607 A Study of NX-1607 in Adults With Advanced Malignancies Recruiting USA | GBR 0
NCT05159518 Phase I PRT2527 A Study of PRT2527 in Participants With Advanced Solid Tumors Completed USA 0
NCT05219500 Phase II FPI-2265 Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST). (TATCIST) Recruiting 0
NCT05241613 Phase I AC176 A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer Terminated USA 0
NCT05256381 Phase II Pembrolizumab + SOT101 A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors Active, not recruiting USA | ITA | FRA | ESP | BEL 4
NCT05369000 Phase Ib/II LAVA-1207 Trial of LAVA-1207 in Patients With Therapy Refractory Metastatic Castration Resistant Prostate Cancer Recruiting USA | NLD | ESP 0
NCT05488548 Phase I NEO2734 Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors Recruiting USA 0
NCT05501548 Phase II Olaparib Phase II Study of PARP Inhibitor Olaparib and IV Ascorbate in Castration Resistant Prostate Cancer Recruiting USA 0
NCT05534646 Phase II Apalutamide Apalutamide + Carotuximab Study of Apalutamide With Carotuximab in Metastatic, Castration-Resistant Prostate Cancer Recruiting USA 0
NCT05592626 Phase Ib/II STAR0602 A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors (START-001) Recruiting USA | CAN 0
NCT05662397 Phase Ib/II HST-1011 Cemiplimab + HST-1011 A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody Recruiting USA 0
NCT05689021 Phase II Niraparib and abiraterone acetate + Prednisone CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations Recruiting USA 0
NCT05700669 Phase Ib/II AsiDNA + Olaparib Study To Assess Safety And Efficacy Of AsiDNA In Combination With Olaparib In Participants With Recurrent Solid Tumors Recruiting USA 0
NCT05730712 Phase II Enzalutamide + Pertuzumab/trastuzumab/hyaluronidase-zzxf Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer, TraPPer Study Recruiting USA 0
NCT05762536 Phase II Docetaxel Cabazitaxel + Darolutamide Darolutamide + Docetaxel Cabazitaxel Docetaxel or Cabazitaxel With or Without Darolutamide in mCRPC (DAROTAXEL) Recruiting NLD 0
NCT05785741 Phase Ib/II DB-1310 A Phase 1/2a Study of DB-1310 in Advanced/Metastatic Solid Tumors Recruiting USA 1
NCT05841563 Phase I PM54 Clinical Trial of PM54 in Advanced Solid Tumors Patients. Recruiting USA | ESP | BEL 0
NCT05914116 Phase Ib/II DB-1311 A Study of DB-1311 in Advanced/Metastatic Solid Tumors Recruiting USA | AUS 0
NCT05917470 Phase Ib/II ONCT-534 A Clinical Study of ONCT-534 in Subjects With Metastatic Castration-resistant Prostate Cancer. Recruiting USA | GBR 0
NCT05999968 Phase I Abemaciclib + Darolutamide Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment Active, not recruiting USA | ESP | DEU 0
NCT06039371 Phase II Etoposide + Testosterone cypionate Carboplatin + Testosterone cypionate Supraphysiological Androgen to Enhance Chemotherapy Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study Recruiting USA 0
NCT06126731 Phase Ib/II Amoxicillin + Enzalutamide + Metronidazole Ciprofloxacin + Enzalutamide + Vancomycin Combination Study of Antibiotics With Enzalutamide (PROMIZE) Recruiting GBR 1
NCT06136624 Phase III Dexamethasone + Fludrocortisone + ODM-208 Enzalutamide Abiraterone Study of MK-5684 Versus Alternative NHA in mCRPC (MK-5684-003) Recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | AUT | AUS 18
NCT06172478 Phase II Patritumab deruxtecan A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors Recruiting 0
NCT06190899 Phase Ib/II Darolutamide + Gedatolisib Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer Recruiting USA | GBR | FRA | ESP 0
NCT06200103 FDA approved lutetium Lu 177 vipivotide tetraxetan Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer Recruiting USA 0
NCT06216249 Phase II lutetium Lu 177 vipivotide tetraxetan Evaluation of a Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer Not yet recruiting USA 0
NCT06217822 Phase I BAY3563254 First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC) (PAnTHA) Recruiting GBR | CAN | BEL 0
NCT06228053 Phase II Enzalutamide + SX-682 Study of SX-682 Plus Enzalutamide in Men With Abiraterone-Resistant Metastatic Castration Resistant Prostate Cancer (SYNERGY-201) Recruiting USA 0
NCT06242470 Phase I MGC026 A Study of MGC026 in Participants With Advanced Solid Tumors Recruiting USA 0
NCT06253130 Phase Ib/II IMP1734 A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors Recruiting USA | AUS 0
NCT06305598 Phase I Leuprolide + Testosterone cypionate Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer Recruiting USA 0
NCT06334432 Phase Ib/II NUV-1511 Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors Recruiting USA 0